No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Samsung Bioepis’ and Celltrion’s Adalimumab Biosimilars Granted Expanded US Interchangeability
On 27 May 2025, Samsung Bioepis announced that it has secured expanded interchangeability designation in the US for its Hadlima™ (adalimumab-aaty), biosimilar to AbbVie’s Humira®…